PATZ1 and diffuse large B-cell lymphoma: To finally assess the impact of PATZ1 expression on patients' outcome, we analysed overall (OS) and progression-free (PFS) survival of DLBCL patients treated with R-CHOP, including a public dataset of 470 patients from the MD Anderson Cancer Center [25], other than 65 patients from our TMA series.